Chinese General Practice ›› 2022, Vol. 25 ›› Issue (26): 3246-3251.DOI: 10.12114/j.issn.1007-9572.2022.0194
• Original Research • Previous Articles Next Articles
Received:
2021-11-20
Revised:
2022-03-20
Published:
2022-09-15
Online:
2022-06-16
Contact:
Pingan ZHANG
About author:
通讯作者:
张平安
作者简介:
基金资助:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.chinagp.net/EN/10.12114/j.issn.1007-9572.2022.0194
组别 | 例数 | 性别〔n(%)〕 | 年龄( | |
---|---|---|---|---|
男 | 女 | |||
对照组 | 95 | 53(55.8) | 42(44.2) | 57.8±12.7 |
非脓毒症组 | 113 | 58(51.3) | 55(48.7) | 60.4±15.7 |
脓毒症组 | 110 | 64(58.2) | 46(41.8) | 61.4±14.8 |
χ2(F)值 | 1.090 | 1.877a | ||
P值 | 0.580 | 0.155 |
Table 1 Comparison of general information of three groups of participants
组别 | 例数 | 性别〔n(%)〕 | 年龄( | |
---|---|---|---|---|
男 | 女 | |||
对照组 | 95 | 53(55.8) | 42(44.2) | 57.8±12.7 |
非脓毒症组 | 113 | 58(51.3) | 55(48.7) | 60.4±15.7 |
脓毒症组 | 110 | 64(58.2) | 46(41.8) | 61.4±14.8 |
χ2(F)值 | 1.090 | 1.877a | ||
P值 | 0.580 | 0.155 |
项目 | 正向(5'-3') | 反向(3'-5') | 片段长度(bp) |
---|---|---|---|
TLR4 | TGAGTTTCAAAGGTTGCTGTTCTC | AGGAATACTGAAAACTCACTCATTTGTT | 178 |
GAPDH | CGGATTTGGTCGTATTGG | GATGATGACCCTTTTGGC | 340 |
Table 2 Sequences of primers for real-time fluorescence quantitative PCR amplification of TLR4 mRNA and GAPDH
项目 | 正向(5'-3') | 反向(3'-5') | 片段长度(bp) |
---|---|---|---|
TLR4 | TGAGTTTCAAAGGTTGCTGTTCTC | AGGAATACTGAAAACTCACTCATTTGTT | 178 |
GAPDH | CGGATTTGGTCGTATTGG | GATGATGACCCTTTTGGC | 340 |
组别 | 例数 | RBC(×109/L) | WBC(×109/L) | NEU(×109/L) | Hb(g/L) | HCT | PLT(×109/L) | ALT(U/L) | AST(U/L) | DBiL(µmol/L) | TBiL(µmol/L) |
---|---|---|---|---|---|---|---|---|---|---|---|
对照组 | 95 | 4.85(0.60) | 6.34(1.73) | 3.54(1.26) | 150.0(17.5) | 0.44(0.06) | 241(111) | 18.0(9.5) | 19(6) | 4.15(1.92) | 13.80(6.90) |
非脓毒症组 | 113 | 4.25(0.84)a | 6.39(3.93)a | 4.29(4.03)a | 124.5(21.5)a | 0.38(0.08)a | 210(111)a | 17.0(22.0)a | 20(11)a | 4.70(4.35)a | 14.60(11.76) |
脓毒症组 | 110 | 3.62(1.20)ab | 12.12(10.51)ab | 11.11(9.17)ab | 102.5(35.2)ab | 0.35(0.19)ab | 125(144)ab | 25.0(56.0)ab | 35(64)ab | 6.80(12.10)ab | 17.41(23.88) |
H值 | 100.173 | 54.549 | 83.666 | 112.046 | 34.99 | 51.266 | 9.745 | 32.646 | 13.555 | 2.019 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.008 | <0.001 | 0.001 | 0.364 |
Table 3 Comparison of laboratory indicators of three groups of patients
组别 | 例数 | RBC(×109/L) | WBC(×109/L) | NEU(×109/L) | Hb(g/L) | HCT | PLT(×109/L) | ALT(U/L) | AST(U/L) | DBiL(µmol/L) | TBiL(µmol/L) |
---|---|---|---|---|---|---|---|---|---|---|---|
对照组 | 95 | 4.85(0.60) | 6.34(1.73) | 3.54(1.26) | 150.0(17.5) | 0.44(0.06) | 241(111) | 18.0(9.5) | 19(6) | 4.15(1.92) | 13.80(6.90) |
非脓毒症组 | 113 | 4.25(0.84)a | 6.39(3.93)a | 4.29(4.03)a | 124.5(21.5)a | 0.38(0.08)a | 210(111)a | 17.0(22.0)a | 20(11)a | 4.70(4.35)a | 14.60(11.76) |
脓毒症组 | 110 | 3.62(1.20)ab | 12.12(10.51)ab | 11.11(9.17)ab | 102.5(35.2)ab | 0.35(0.19)ab | 125(144)ab | 25.0(56.0)ab | 35(64)ab | 6.80(12.10)ab | 17.41(23.88) |
H值 | 100.173 | 54.549 | 83.666 | 112.046 | 34.99 | 51.266 | 9.745 | 32.646 | 13.555 | 2.019 | |
P值 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | <0.001 | 0.008 | <0.001 | 0.001 | 0.364 |
组别 | 例数 | qSOFA〔M(QR),分〕 | 感染病原〔n(%)〕 | ||||||
---|---|---|---|---|---|---|---|---|---|
革兰阳性菌 | 革兰阴性菌 | 真菌 | 病毒 | 支原体 | 多重感染 | 未知病原 | |||
非脓毒症组 | 113 | 1.0(1.0) | 18(15.9) | 45(39.8) | 9(7.96) | 2(1.77) | 2(1.77) | 6(5.31) | 31(27.4) |
脓毒症组 | 110 | 1.1(1.0) | 7(6.4) | 32(29.1) | 14(12.7) | 6(5.45) | 1(0.91) | 4(3.64) | 46(41.8) |
Z(χ2)值 | -3.128 | 13.739a | |||||||
P值 | 0.002 | 0.033 | |||||||
组别 | 感染部位〔n(%)〕 | ||||||||
肺 | 血液 | 腹腔 | 肝胆系统 | 泌尿系统 | 皮肤和软组织 | 中枢神经系统 | 其他 | ||
非脓毒症组 | 35(31.0) | 1(0.9) | 6(5.3) | 10(8.8) | 28(24.8) | 15(13.3) | 6(5.3) | 12(10.6) | |
脓毒症组 | 46(41.8) | 5(4.5) | 9(8.2) | 15(13.6) | 23(20.9) | 5(4.5) | 1(0.9) | 6(5.5) | |
Z(χ2)值 | 16.785a | ||||||||
P值 | 0.019 |
Table 4 qSOFA scores,pathogens and infected sites in non-sepsis and sepsis groups
组别 | 例数 | qSOFA〔M(QR),分〕 | 感染病原〔n(%)〕 | ||||||
---|---|---|---|---|---|---|---|---|---|
革兰阳性菌 | 革兰阴性菌 | 真菌 | 病毒 | 支原体 | 多重感染 | 未知病原 | |||
非脓毒症组 | 113 | 1.0(1.0) | 18(15.9) | 45(39.8) | 9(7.96) | 2(1.77) | 2(1.77) | 6(5.31) | 31(27.4) |
脓毒症组 | 110 | 1.1(1.0) | 7(6.4) | 32(29.1) | 14(12.7) | 6(5.45) | 1(0.91) | 4(3.64) | 46(41.8) |
Z(χ2)值 | -3.128 | 13.739a | |||||||
P值 | 0.002 | 0.033 | |||||||
组别 | 感染部位〔n(%)〕 | ||||||||
肺 | 血液 | 腹腔 | 肝胆系统 | 泌尿系统 | 皮肤和软组织 | 中枢神经系统 | 其他 | ||
非脓毒症组 | 35(31.0) | 1(0.9) | 6(5.3) | 10(8.8) | 28(24.8) | 15(13.3) | 6(5.3) | 12(10.6) | |
脓毒症组 | 46(41.8) | 5(4.5) | 9(8.2) | 15(13.6) | 23(20.9) | 5(4.5) | 1(0.9) | 6(5.5) | |
Z(χ2)值 | 16.785a | ||||||||
P值 | 0.019 |
组别 | 例数 | 外周血单个核细胞TLR4 mRNA | PCT(μg/L) |
---|---|---|---|
对照组 | 95 | 0.029(0.036) | 0.003(0.001) |
非脓毒症组 | 113 | 0.049(0.081)a | 0.020(0.723)a |
脓毒症组 | 110 | 0.116(0.145)ab | 2.49(21.290)ab |
H值 | 81.938 | 96.047 | |
P值 | <0.01 | <0.01 |
Table 5 TLR4 mRNA in peripheral blood mononuclear cells and serum PCT in three groups of patients
组别 | 例数 | 外周血单个核细胞TLR4 mRNA | PCT(μg/L) |
---|---|---|---|
对照组 | 95 | 0.029(0.036) | 0.003(0.001) |
非脓毒症组 | 113 | 0.049(0.081)a | 0.020(0.723)a |
脓毒症组 | 110 | 0.116(0.145)ab | 2.49(21.290)ab |
H值 | 81.938 | 96.047 | |
P值 | <0.01 | <0.01 |
[1] |
|
[2] |
|
[3] |
|
[4] |
牛秋丽,张鑫,王晶,等. PLR和NLR在老年脓毒症患者中的应用价值[J]. 医学研究杂志,2021,50(9):124-126,132. DOI:10.11969/j.issn.1673-548X.2021.09.028.
|
[5] |
|
[6] |
|
[7] |
|
[8] |
|
[9] |
|
[10] |
|
[11] |
|
[12] |
|
[13] |
|
[14] |
|
[15] |
|
[16] |
|
[17] |
|
[18] |
|
[19] |
|
[20] |
|
[21] |
|
[22] |
|
[23] |
|
[24] |
胡世宇,张泓. 降钙素原变化率及C-反应蛋白变化率对脓毒性休克评估的价值[J]. 中国急救医学,2021,41(6):506-510. DOI:10.3969/j.issn.1002-1949.2021.06.011.
|
[1] | WANG Yu, CHEN Yan, HAN Yuanyuan, XU Qing, CHEN Shengyue, LYU Zhibo, LU Chuan, ZHENG Mingxin, ZHAO Xin. Platelet-lymphocyte Ratio Predicts In-hospital Mortality in Elderly Patients with Acute Myocardial Infarction [J]. Chinese General Practice, 2023, 26(33): 4137-4142. |
[2] | ZHANG Jifang, CHEN Fang, TANG Jiawen, LI Hongliang. Predictive Value of Tumor Budding and Tumor-infiltrating Lymphocytes on Lymph Node Metastasis of Esophageal Squamous Cell Carcinoma [J]. Chinese General Practice, 2023, 26(32): 4038-4042. |
[3] | HONG Yuchun, WU Hua, DU Yishan, LI Shuran, SUN Wenmin, YE Mingyu, ZHANG Yongjian, LI Yang. Development of General Practice Diagnostic Terminology and Coding and Empirical Study on Its Application [J]. Chinese General Practice, 2023, 26(31): 3896-3901. |
[4] | WEN Wen, ZHANG Kainan, CHEN Yulan, LI Yu, ZHANG Xiangyang. Correlation of Metabolic Indexes as Predictors with Obstructive Sleep Apnea [J]. Chinese General Practice, 2023, 26(30): 3740-3747. |
[5] | CHEN Jing, ZOU Tao, ZHAO Danqing, XIAO Ziwen, WU Xianqing, Chinese Medical Association Psychosomatic Medicine Branch Perinatal Mental Disorders Collaborative Group. Expert Consensus on Screening, Diagnosis and Treatment of Perinatal Mental Disorders [J]. Chinese General Practice, 2023, 26(28): 3463-3470. |
[6] | Expert group of expert consensus on the application of ulinastatin in common clinical critical illness. Expert Consensus on the Application of Ulinastatin in Common Clinical Critical Illness [J]. Chinese General Practice, 2023, 26(26): 3207-3219. |
[7] | YIN Zhaoxia, KONG Chongyu, ZOU Xianhui, LI Chuang, HUANG Yin, FENG Yang, WANG Yunfei, GONG Weijie. Traditional Chinese Medicine Disease Spectrum Analysis in Outpatient Clinics of Contracted Residents by Family Doctors in Shenzhen Community Health Service Centers [J]. Chinese General Practice, 2023, 26(25): 3112-3117. |
[8] | ZHANG Yunxu, WANG Tingting, WEI Junling, XING Yanyun, SU Li. A Newly Discovered Disease Affecting Women's Physical and Mental Health: Research Status and Expert Consensus Interpretation of Persistent Genital Arousal Disorder [J]. Chinese General Practice, 2023, 26(23): 2830-2835. |
[9] | ZHANG Yanjing, SONG Xiaokun. Ideas for the Diagnosis and Treatment of Multisystem Immune-related Adverse Events Caused by Immune Checkpoint Inhibitors [J]. Chinese General Practice, 2023, 26(23): 2930-2935. |
[10] | HU Xiaofei, ZHAO Ping, CAO Tinghua, PENG Lanlan. Study on the Predictive Value of Abdominal Fat Content and Distribution in the Acute Pancreatitis and Its Severity [J]. Chinese General Practice, 2023, 26(21): 2614-2619. |
[11] | SHEN Junxi, ZHU Xing, CHEN Yunzhi, LI Wen. Novel Developments in Lung and Gut Microbiota and Their Cross-talk with the Development of Chronic Obstructive Pulmonary Disease [J]. Chinese General Practice, 2023, 26(20): 2548-2554. |
[12] | REN Yumei, XU Min, YE Meilei, ZHANG Qiu, HU Honglin. A Mutation in the Insulin Receptor Substrate 2 Gene May Be Associated with Maturity-onset Diabetes of the Young: a Case Report with Genetic Analysis [J]. Chinese General Practice, 2023, 26(18): 2301-2305. |
[13] | WANG Hai, WANG Zhuoli, PEI Honghong, PAN Longfei. Analysis of Risk Factors and Exploration of Predictors of Serious Cases of COVID-19 in Xi'an during the Period of 2021-2022 [J]. Chinese General Practice, 2023, 26(17): 2132-2137. |
[14] | LIANG Shanshan, ZHOU Zhihua, LI Chengcheng, CHEN Huijing, ZHOU Shangcheng. Diabetes in China: Burden Analysis between 1990 and 2019 and Incidence Prediction between 2020 and 2030 [J]. Chinese General Practice, 2023, 26(16): 2013-2019. |
[15] | XU Bixia, YAO Weiguang. Changes in Patient Visits and Associated Determinants in Primary Healthcare Settings in Guangdong: a Grey Relational Analysis [J]. Chinese General Practice, 2023, 26(16): 1965-1971. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||